Wegovy Side Effects and Cancer: What the Research Shows

Has semaglutide been linked to cancer in human studies?

The short answer is that human trial data have not shown semaglutide to cause cancer. The STEP clinical programme (the large trials that led to Wegovy's UK licence) included thousands of adults followed for up to 68 weeks. No statistically significant increase in cancer rates was found among participants taking semaglutide 2.4mg compared with placebo, as reported in the STEP 1 trial published in the New England Journal of Medicine.

A separate large cardiovascular outcomes trial (SELECT) followed over 17,000 adults with obesity and established cardiovascular disease for around four years. Again, no causal link to cancer emerged. Researchers did observe, in post-hoc analysis, a potentially lower rate of certain obesity-related cancers in the semaglutide group, but that is an association requiring far more investigation, not a proven benefit or a proven risk.

The honest position is this: the evidence base is real but still maturing. Wegovy only received its UK weight-management licence in 2021, and if you want a detailed breakdown of what is and is not currently known, our page on Wegovy cancer risk covers the evidence as it stands. Regulators and researchers are watching actively, which is exactly what should happen with any newer medicine.

What is the thyroid concern, and does it apply to semaglutide in humans?

This is the cancer question most people are actually asking about. In rodent studies, GLP-1 receptor agonists including semaglutide caused thyroid C-cell tumours (a type called medullary thyroid carcinoma, or MTC). That finding was prominent enough to shape prescribing rules worldwide.

The catch is that rodent thyroid C-cells express GLP-1 receptors far more densely than human ones do, which may explain why the same effect has not appeared in human trials. As the NHS semaglutide medicines page notes, Wegovy is not recommended for people with a personal or family history of MTC, or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). That remains a firm contraindication regardless of where you obtain treatment.

If you notice a lump in your neck, persistent hoarseness, difficulty swallowing, or shortness of breath while taking Wegovy, contact your GP or prescriber promptly. These are the symptoms associated with thyroid changes and should always be assessed. The contraindication for MTC and MEN2 exists precisely because the theoretical risk cannot be ruled out in susceptible individuals.

When do you need medical help urgently?

Most people's experience of Wegovy's side effects centres on the gut: nausea, loose stools, constipation, indigestion. Those are well-documented and typically settle within a few weeks of starting or stepping up a dose. You can read more about the full range in our overview of Wegovy side effects.

Some symptoms need same-day or emergency attention. Severe, persistent stomach pain that spreads toward your back (with or without vomiting) may indicate acute pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update on GLP-1 medicines. Call 111 or go to A&E; do not wait to see if it passes.

Other urgent signals include signs of a severe allergic reaction (swelling of the face, lips or throat, difficulty breathing), symptoms of gallbladder problems (sharp pain in the upper-right abdomen, fever, jaundice), significant dehydration from prolonged vomiting or diarrhoea, and any new lump in the neck as described above. If you notice low mood, unusual thoughts, or other changes to your mental health, our page on semaglutide and mental side effects covers what is known. Contact your prescriber or seek emergency care depending on severity.

Suspected side effects (including anything cancer-related you notice on treatment) can be reported directly to the MHRA via the Yellow Card scheme. You do not need a medical professional to file a report; patients can do it themselves. Those reports genuinely feed into ongoing safety monitoring.

How does nume approach semaglutide safety before prescribing?

Our prescribers are GPhC-registered Independent Prescribers, a real clinician reads your consultation, not software. They review your personal and family medical history, including anything that would make Wegovy unsuitable: thyroid conditions, pancreatitis history, MEN2, pregnancy, and more. If you are not suitable, you are told clearly and not approved. That review happens the same day your consultation comes in, every time.

Some people find it reassuring to read about the wider Wegovy treatment overview before starting, or to explore how some people experience no significant side effects at all. Equally, the five most commonly reported side effects are worth understanding so you know what is normal and what is not. If you have already started treatment and something feels wrong, our team is available seven days a week.

If you are weighing up whether Wegovy is the right option, our prescribers discuss suitability, side effects, and your individual history as part of the free consultation. That conversation is where cancer history, thyroid concerns and any other flag gets properly assessed, not filtered out by a tick-box algorithm.